Immunovant/$IMVT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
- Ticker
- $IMVT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 315
- Headquarters
- Durham, United States
- Website
- immunovant.com
Immunovant Metrics
BasicAdvanced
$6B
-
-$2.82
0.81
-
Price and volume
Market cap
$6B
Beta
0.81
52-week high
$45.42
52-week low
$21.43
Average daily volume
1.5M
Financial strength
Current ratio
7.269
Quick ratio
6.819
Profitability
EBITDA (TTM)
-565.607
Effective tax rate (TTM)
0.13%
Management effectiveness
Return on assets (TTM)
-46.73%
Return on equity (TTM)
-80.10%
Valuation
Price to book
8.18
Price to tangible book (TTM)
8.18
Price to free cash flow (TTM)
-13.454
Free cash flow yield (TTM)
-7.43%
Free cash flow per share (TTM)
-2.168
Growth
Earnings per share change (TTM)
-0.66%
3-year earnings per share growth (CAGR)
13.39%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Analyst projections of the future price of Immunovant stock.
Bulls say / Bears say
At Week 16, the open-label difficult-to-treat rheumatoid arthritis study showed ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8%. This is an encouraging early signal in a heavily treated group, although controlled confirmation is still needed. (Immunovant)
Phase 1 results suggest IMVT-1402 may reduce IgG deeply while having little effect on albumin or LDL, potential advantages over FcRn drugs associated with these off-target changes. A differentiated profile could support use across chronic autoimmune conditions. (MarketScreener)
Immunovant is advancing IMVT-1402 in several other autoimmune diseases, with potentially registrational studies in Graves’ disease and myasthenia gravis due to report in 2027, followed by CIDP and Sjögren’s disease in 2028. That gives the drug several opportunities to demonstrate value beyond one indication. (Immunovant, Immunovant)
IMVT-1402 missed the primary endpoint in its 57-patient cutaneous lupus study, and the company plans to stop development in that indication. The result is a clear loss of one potential market and raises questions about how reliably IgG reduction will translate into clinical benefit. (Immunovant)
The rheumatoid arthritis response rates came from an open-label study period, without a concurrent placebo group. They are therefore not yet proof that IMVT-1402 caused the improvement, leaving a key efficacy question unresolved. (Immunovant)
Cash was $797.8 million at the end of June, but management’s stated runway only extends to a potential Graves’ disease launch under its current plan. Quarterly cash use was $124.4 million, and the company says it may need more capital to fund its broader development plans, creating financing and dilution risk. (Immunovant, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunovant News
AllArticlesVideos
Funds containing Immunovant
AllUSDEURGBP
Fund name | Fund size | $IMVT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.39% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.39% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.